Adapting the UK Biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors
Adapting the UK Biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors
复制标题
调整英国生物银行脑成像协议和分析流程以进行 COVID-19 幸存者的 C-MORE 多器官研究
DOI：
10.1101/2021.05.19.21257316
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Griffanti L
中科院分区：
文献类型：
--
作者：
Griffanti L
SARS-CoV-2感染已被证明会损害多个器官，包括大脑。多器官MRI可以进一步了解COVID-19对器官健康的影响，但需要在数据采集的丰富性和质量以及总扫描时间之间取得平衡。我们调整了英国生物银行的脑部MRI方案，以产生高质量的图像，同时适合作为COVID-19后多器官MRI检查的一部分。分析流程也是从英国生物银行改编的，包括新的成像衍生表型（IDP），旨在评估COVID-19的可能影响。在参与Oxford C-MORE研究的51名COVID-19患者出院后和25名对照患者中首次应用了该方案和管道。该协议在17分钟内采集高分辨率T1、T2-FLAIR、弥散加权图像、磁敏感加权图像和动脉自旋标记数据。自动成像管道可获得1，575个IDP，评估大脑解剖结构（包括嗅球体积和强度）和组织灌注、高信号、弥散度和磁敏感性。在C-MORE数据中，与萎缩、小血管疾病和嗅球相关的IDP与临床放射学报告一致。我们的探索性分析初步揭示了COVID-19康复患者和对照组之间的一些组间差异，在严重程度组之间，但在嗅觉丧失组之间没有。C-MORE研究中的随访成像目前正在进行中，该方案目前正在其他大规模研究中使用。该方案、管道代码和数据是公开的，将进一步有助于了解COVID-19的中长期影响。
SARS-CoV-2 infection has been shown to damage multiple organs, including the brain. Multiorgan MRI can provide further insight on the repercussions of COVID-19 on organ health but requires a balance between richness and quality of data acquisition and total scan duration. We adapted the UK Biobank brain MRI protocol to produce high-quality images while being suitable as part of a post-COVID-19 multiorgan MRI exam. The analysis pipeline, also adapted from UK Biobank, includes new imaging-derived phenotypes (IDPs) designed to assess the possible effects of COVID-19. A first application of the protocol and pipeline was performed in 51 COVID-19 patients post-hospital discharge and 25 controls participating in the Oxford C-MORE study. The protocol acquires high resolution T1, T2-FLAIR, diffusion weighted images, susceptibility weighted images, and arterial spin labelling data in 17 min. The automated imaging pipeline derives 1,575 IDPs, assessing brain anatomy (including olfactory bulb volume and intensity) and tissue perfusion, hyperintensities, diffusivity, and susceptibility. In the C-MORE data, IDPs related to atrophy, small vessel disease and olfactory bulbs were consistent with clinical radiology reports. Our exploratory analysis tentatively revealed some group differences between recovered COVID-19 patients and controls, across severity groups, but not across anosmia groups. Follow-up imaging in the C-MORE study is currently ongoing, and this protocol is now being used in other large-scale studies. The protocol, pipeline code and data are openly available and will further contribute to the understanding of the medium to long-term effects of COVID-19.